

Who's Leading the Antibody Drug Conjugates Contract Manufacturing Market? A Deep Dive into Competitive Positioning

The Business Research Company's Who's Leading the Antibody Drug Conjugates Contract Manufacturing Market? A Deep Dive into Competitive Positioning

LONDON, GREATER LONDON, UNITED KINGDOM, April 28, 2026

/EINPresswire.com/ -- "The antibody drug conjugates contract manufacturing market is dominated by a mix of global contract development and manufacturing organizations (CDMOs) and specialized bioconjugation service providers.

Companies are focusing on advanced linker-payload technologies, high-containment manufacturing capabilities, scalable production processes, and stringent regulatory compliance to strengthen market presence and ensure product safety and efficacy. Emphasis on technological expertise, capacity expansion, strategic collaborations, and end-to-end service

“


Expected to grow to \$16.5 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%”

The Business Research Company

integration remains central to maintaining competitive advantage. Understanding the competitive landscape is essential for stakeholders seeking growth opportunities, innovation in targeted therapies, and strategic partnerships within the rapidly evolving oncology and biopharmaceutical sectors.

Which Market Player Is Leading The Antibody Drug Conjugates Contract Manufacturing Market?

•According to our research, Lonza Group AG led global sales in 2024 with a 2% market share. The company's contract development and manufacturing division, actively engaged in the antibody drug conjugates contract manufacturing market, offers integrated services including bioconjugation, cytotoxic payload handling, and aseptic fill-finish capabilities that support oncology therapeutics development and commercialization under highly regulated conditions.



Who Are The Major Players In The Antibody Drug Conjugates Contract Manufacturing Market?

Major companies operating in the antibody drug conjugates contract manufacturing market are Lonza Group AG, Thermo Fisher Scientific Inc., Catalent Inc., Samsung Biologics Co., Merck KGaA, Recipharm AB, Sterling Pharma Solutions Limited, Curia Global Inc., Formosa Laboratories Inc., EirGenix Inc., Cerbios-Pharma SA, Alcam Corporation, Avid Bioservices Inc., Creative Biolabs Inc., BioVectra Inc., Axplora Group GmbH, Aurigene Pharmaceutical Services Ltd., Abzena PLC

How Concentrated Is The Antibody Drug Conjugates Contract Manufacturing Market?

•The market is fragmented, with the top 10 players accounting for 10% of total market revenue in 2024. This level of concentration reflects moderate technological complexity alongside increasing participation from specialized contract manufacturing organizations, driven by rising demand for targeted biologics, flexible manufacturing capabilities, and cost-efficient outsourcing models. Leading players such as Lonza Group AG, Thermo Fisher Scientific Inc., Catalent Inc., Samsung Biologics Co. Ltd., Merck KGaA, Recipharm AB, Sterling Pharma Solutions Limited, Curia Global Inc., Formosa Laboratories Inc., and EirGenix Inc. hold relatively smaller individual market shares due to the presence of numerous regional and niche service providers offering antibody drug conjugate (ADC) development and manufacturing services. As demand for oncology-focused therapeutics, advanced conjugation technologies, and scalable biomanufacturing solutions grows, strategic partnerships, technological advancements, and capacity expansions are expected to enhance competitive dynamics and gradually consolidate portions of the market.

•Leading companies include:

- oLonza Group AG (2%)
- oThermo Fisher Scientific Inc. (2%)
- oCatalent Inc. (2%)
- oSamsung Biologics Co. Ltd. (1%)
- oMerck KGaA (1%)
- oRecipharm AB (1%)
- oSterling Pharma Solutions Limited (1%)
- oCuria Global Inc. (1%)
- oFormosa Laboratories Inc. (0.2%)
- oEirGenix Inc. (0.2%)

Request A Free Sample Of The Antibody Drug Conjugates Contract Manufacturing Market Report

https://www.thebusinessresearchcompany.com/sample_request?id=18954&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Who Are The Key Raw Material Suppliers In The Antibody Drug Conjugates Contract Manufacturing Market?

•Major raw material suppliers in the antibody drug conjugates contract manufacturing market

include Merck KGaA, Sartorius AG, Cytiva, Lonza Group AG, Thermo Fisher Scientific Inc., Ajinomoto Bio Pharma Services Inc., WuXi AppTec Co Ltd, Cambrex Corporation, Sterling Pharma Solutions Limited, Johnson Matthey Plc, Piramal Pharma Limited, Novasep Holding SAS, CordenPharma International GmbH, Almac Group Limited, BioVectra Inc., Cerbios Pharma SA, BSP Pharmaceuticals SpA, Regis Technologies Inc., ChemPartner, Syngene International Limited, Laurus Labs Limited, Divis Laboratories Limited, Dishman Carbogen Amcis Limited, Aurigene Pharmaceutical Services Limited, and Anthem Biosciences Private Limited.

Who Are The Leading Wholesalers Or Distributors In The Antibody Drug Conjugates Contract Manufacturing Market?

- Major wholesalers or distributors in the antibody drug conjugates contract manufacturing market include Avantor Inc., VWR International LLC, Univar Solutions Inc., Brenntag SE, IMCD NV, DKSH Holding Ltd., Azelis Group NV, Barentz International BV, Biotage AB, Repligen Corporation, Pall Corporation, Tokyo Chemical Industry Co Ltd, Fujifilm Irvine Scientific Inc., Spectrum Chemical Manufacturing Corp., LGC Limited, MP Biomedicals LLC, Bio Rad Laboratories Inc., Takara Bio Inc., Promega Corporation, GenScript Biotech Corporation, Bachem Holding AG, PeproTech Inc., Rockland Immunochemicals Inc., and Nordmann Rassmann GmbH.

Who Are The Major End Users Of The Antibody Drug Conjugates Contract Manufacturing Market?

- Major end users in the antibody drug conjugates contract manufacturing market include F Hoffmann La Roche Ltd, Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Seagen Inc., Daiichi Sankyo Company Limited, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., ImmunoGen Inc., ADC Therapeutics SA, Mersana Therapeutics Inc., Sutro Biopharma Inc., Zymeworks Inc., BeiGene Ltd., Innovent Biologics Inc., Shanghai Miracogen Inc., LegoChem Biosciences Inc., and Chia Tai Tianqing Pharmaceutical Group Co Ltd.

What Are The Major Competitive Trends In The Market?

- Expanding end-to-end integrated ADC/XDC solutions is transforming the antibody drug conjugates contract manufacturing market by enhancing production efficiency, increasing capacity, and enabling seamless development from antibody drug substance to finished drug product.
- Example: In March 2025, ChemExpress launched its Chongqing Haoyuan Biopharmaceutical Co., Ltd. GMP facility, a 56,000m² site dedicated to ADC/XDC contract development and manufacturing, offering 8,000-litre antibody drug substance capacity, over 80 payloads and 400 linkers, multiple bioconjugation techniques, and up to 2 million bottles annually.
- Its integrated manufacturing capabilities, broad payload-linker portfolio, and scalable bioconjugation technologies accelerate clinical development timelines, support global biopharmaceutical innovation, and strengthen the commercialization of next-generation ADC/XDC therapeutics.

Which Strategies Are Companies Adopting To Stay Ahead?

- Enhancing ADC Manufacturing Flexibility Through Adoption Of Single-Use Reactor Technologies
- Accelerating ADC Production And Commercialization With Advanced GMP-Compliant DP3 Facilities
- Strengthening End-To-End ADC Manufacturing Capabilities Through Full-Scale Facility Expansion
- Expanding ADC Production Capacity Through Advanced Manufacturing Suites And Integrated Solutions

Access The Detailed Antibody Drug Conjugates Contract Manufacturing Market Report Here
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-contract-manufacturing-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
[LinkedIn](#)
[Facebook](#)
[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/908734622>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.